Pathways for Cholesterol and Bile Acid Biosynthesis
===================================================

Cholesterol homeostasis in human is maintained by two input pathways, comprised of dietary absorption and *de novo* synthesis, and two output pathways, comprised of direct secretion from liver to bile and conversion into bile acids ([@b17-aci-3-45]). The rate-limiting step in the *de novo* cholesterol synthesis is the conversion of 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) into mevalonic acid (MVA) by HMG-CoA reductase (HMGCR) ([@b12-aci-3-45]). In contrast, the bile acid biosynthetic pathway is initiated by either hepatic 7α-hydroxylation or hepatic and extrahepatic 27-hydroxylation of cholesterol. The former is catalyzed by microsomal cholesterol 7α-hydroxylase (CYP7A1), the first and rate-limiting enzyme in the classic pathway, while the latter is catalyzed by mitochondrial sterol 27-hydroxylase (CYP27A1), a key enzyme in the alternative pathway ([@b79-aci-3-45]). Bile acid synthesis by the classic pathway accounts for more than 90% of total bile acids in humans ([@b14-aci-3-45]) while less than 50% of total bile acids is produced by this pathway in rats ([@b80-aci-3-45]) and mice ([@b69-aci-3-45]). Therefore, the measurement of CYP7A1 activity is more important than that of CYP27A1 activity for the evaluation of bile acid biosynthesis in humans.

Direct and Indirect Assays of HMGCR and CYP7A1 Activities
=========================================================

Since HMGCR and CYP7A1 are crucial enzymes in understanding whole body cholesterol metabolism, a great deal of effort has been made to develop suitable assay methods for these enzyme activities. The primary methods have the great disadvantage that an invasive tissue biopsy is necessary for direct determination of these enzyme activities in humans. To overcome this problem, plasma biomarkers for evaluation of these enzyme activities has been explored.

Plasma levels of MVA, the immediate product of HMGCR, were positively correlated with HMGCR activities in rat liver ([@b61-aci-3-45]). In humans, the plasma MVA concentrations reflected (i) increased rates of whole-body cholesterol synthesis by treatment with cholestyramine resin, and (ii) decreased rates of whole-body sterol synthesis after consumption of a cholesterol-rich diet ([@b56-aci-3-45] and [@b57-aci-3-45]). In addition, plasma concentration of lathosterol, an intermediate in the late cholesterol biosynthetic pathway, was reported to reflect hepatic HMGCR activity ([@b6-aci-3-45]) as well as whole body cholesterol synthesis ([@b34-aci-3-45]) in humans.

As for bile acid biosynthesis, Björkhem et al. ([@b7-aci-3-45]) demonstrated that serum levels of 7α-hydroxycholesterol (7A) correlated well with the activities of CYP7A1 in patients with gallstones treated with cholestyramine. In addition, Axelson et al. ([@b3-aci-3-45]) measured serum concentrations of 7α-hydroxy-4-cholesten-3-one (C4), the product of the next reaction following 7α-hydroxylation of cholesterol, and showed that it was a good marker for CYP7A1 activity in humans ([@b4-aci-3-45]). It was subsequently reported that serum concentrations of 7A ([@b24-aci-3-45]) and C4 ([@b65-aci-3-45]) reflected not only CYP7A1 activities but also bile acid synthesis in humans.

The Methods for the Quantification of MVA
=========================================

[Table 1](#t1-aci-3-45){ref-type="table"} summarizes the previously described methods for the quantification of MVA in the liver (enzyme assay), plasma or urine. The primary methods for assaying HMGCR activity have utilized a RI technique that measures the radioactivity in \[^14^C\]MVA produced from \[^14^C\]HMG-CoA ([@b72-aci-3-45]; [@b22-aci-3-45]; [@b74-aci-3-45]). The methods have been used for the direct determination of enzyme activity but they are not applicable to the quantification of plasma or urinary MVA. In contrast, the following methods, i.e. radioenzymatic assay, enzyme immunoassay, gas chromatography-mass spectrometry (GC-MS), high-performance liquid chromatography (HPLC), liquid chromatography-mass spectrometry (LC-MS) and liquid chromatography-tandem mass spectrometry (LC-MS/MS), can measure not only enzyme activity but also MVA concentrations in plasma and urine.

Radioenzymatic assay
--------------------

Radioenzymatic assay of the plasma MVA concentration was reported by Popjak et al. ([@b61-aci-3-45]). The method depends on the phosphorylation of MVA with \[γ-^32^P\]ATP and MVA kinase to 5-\[^32^P\]phospho-MVA, and the subsequent isolation of the 5-\[^32^P\]phospho-MVA together with known amounts of added 5-phospho\[^14^C\]MVA by ion-exchange chromatography. The detection limit of their radioenzymatic assay was 1--2 pmol (148--296 pg) indicating that it was not adequate for determining MVA in small amounts of plasma. In addition, there was a safety concern due to the handling of radioactive materials.

Enzyme immunoassay
------------------

In 1998, Hiramatsu et al. developed an enzyme immunoassay for urinary MVA using a specific monoclonal antibody against MVA ([@b25-aci-3-45]). This method is not only simpler than the previously described radioenzymatic assay but also completely avoids the risk of radiation hazards. However, the limit of detection was not better than that of the radioenzymatic assay.

GC-MS
-----

In 1972, Hagenfeldt and Hellström attempted to determine MVA concentration in rat blood by using GC-MS ([@b23-aci-3-45]). In this procedure, the MVA was extracted from the acid aqueous phase as the lactone. The lactonization increased the hydrophobicity of MVA, so that they could extract it into organic phase. The resulting extract was treated with diazomethane to convert the coexisting fatty acids into their methyl esters. The unchanged mevalonolactone (MVL) with diazomethane in the extract was quantified by GC-MS in electron ionization mode (GC-EI-MS). The peak corresponding to the retention time of MVL appeared large due to interfering materials, such as fatty acids. However, the MVL could be quantified selectively because MVL exhibited an intensive peak at m/z 71 in the spectrum, whereas all fatty acid methyl esters gave rise to the inherent peak at m/z 74 produced by the McLafferty rearrangement ion of the methyl ester. Since then, urinary MVA has been successfully quantified by a similar GC-EI-MS method described above ([@b81-aci-3-45]).

In the 1970s, the RI technique was the standard method for assaying HMGCR activity, but the handling of radiolabeled materials was a great disadvantage of this method. In 1978, Miyazaki et al. developed a new non-RI method for assaying HMGCR activity in rat liver microsomes or liver slices using \[^2^H~3~\]HMG-CoA as a substrate and GC-MS in chemical ionization mode (GC-CI-MS) ([@b40-aci-3-45]). In this method, the resulting \[^2^H~3~\]MVL was derivatized to the corresponding n-propylamide-n-butylboronate, and deuterium labeled \[^2^H~7~\]MVL was first used as an internal standard.

In 1991, Scoppola et al. ([@b70-aci-3-45]) extended this approach, and quantified plasma MVA concentrations. The MVA was lactonized, extracted with \[^2^H~3~\]MVL and reconverted to the free acid. The resulting MVA was then converted to 3,5-bis(trifluoromethyl)benzyl ester followed by its trimethylsilyl (TMS) ether derivative. The quantification method was based on GC-CI-MS using ammonia as a reagent gas and the detection limit of MVA in plasma was 100 pg/mL. The GC-CI-MS method for the quantification of plasma MVA was subsequently improved by Ishihama et al. ([@b32-aci-3-45]) and Saisho et al. ([@b64-aci-3-45]), and the method for the determination of urinary MVA was developed by Siavoshian et al. ([@b78-aci-3-45]). However, the GC-CI-MS methods have one disadvantage in that they required frequent cleaning of the CI ion source to maintain the high sensitivity.

To eliminate the aforementioned tedious operations in GC-CI-MS, another approach by gas chromatography-electron ionization-mass spectrometry (GC-EI-MS) was also developed. Cighetti et al. ([@b10-aci-3-45]; [@b18-aci-3-45]) assayed HMGCR activity by GC-EI-MS after conversion of MVL into the corresponding trimethylsilyl (TMS) ether. They used the ions at m/z 187 (M--15) for MVL-TMS and m/z 150 (M--15--CH~2~CO) for \[^2^H~5~\]MVL-TMS because these ions were not influenced by interfering peaks in extracts from liver microsomes. In 1989, the same group improved their original method by using GC-high-resolution (HR)-EI-MS ([@b11-aci-3-45]). This group lactonized plasma and urinary MVA into MVL using a cation exchange resin, and extracted with organic solvent after the addition of \[^2^H~5~\]MVL as an internal standard. The extracted MVL was then converted into the TMS ether derivative, and quantified by GC-HR-EI-MS with a mass spectral resolution of 5,000. The ions at m/z 145.0685 for MVL-TMS and m/z 150.0965 for \[^2^H~5~\]MVL-TMS were used for selected ion monitoring (SIM).

We also developed new assay methods to measure hepatic HMGCR activity ([@b27-aci-3-45]) and plasma MVA concentration ([@b83-aci-3-45]) by GC-HR-EI-MS. These methods made it possible to simultaneously quantify not only MVA but also 7A. Other features of these methods are described below.

i.  A purification procedure was developed by the serial use of commercially available solid-phase extraction cartridges, which provided high recovery and reproducibility. In brief, plasma MVA was extracted by an anion exchange Bond Elut SAX cartridge, and then eluted as MVL with 0.6 M HCl. The MVL was further purified by a reversed phase Bond Elut C18 and a normal phase Bond Elut CN cartridges. In addition, an excess benzylamine was removed by another Bond Elut CN cartridge after derivatization into mevalonylbenzylamide. The recovery of spiked MVA through the purification procedures using these cartridges was 94.1%, and the relative standard deviations between sample preparations and between measurements by this method were 5.6% and 2.8%, respectively ([@b83-aci-3-45]).

ii. \[^2^H~7~\]MVL was used as an internal standard. This hepta-deuterated variant of MVL provided both good linearity of the calibration curve and easiness to distinguish between MVL peak and interfering peaks even if the MVL peak was small.

iii. MVL was easily converted into mevalonylbenzylamide without any catalyst under mild conditions followed by its dimethylethylsilyl (DMES) ether derivative. This amidation via MVL from MVA is a characteristic reaction for γ-hydroxyfatty acids, such as MVA, however, the free fatty acids also present in the extract did not react without catalysts. The resulting derivative gave a \[M-C~2~H~5~\]^+^ ion at *m/z* 380.2077 with a prominent intensity in the high mass region, which was a great advantage in the elimination of interfering peaks originating from endogenous substances in the extract by GC-EI-MS.

iv. The DMES ether derivative was much more stable than the TMS ether derivative.

v.  The MVL derivative was quantified by GC-HR-EI-MS with a mass spectral resolution of 10,000, which was also useful to eliminate peaks of unknown substances that could interfere with the monitoring.

vi. Trace amounts, less than 1 pg, of MVA could be detected by this method, and the lower limit of quantification in plasma sample was 180 pg/mL.

vii. Using these methods, it was validated that there was a highly significant correlation between the hepatic HMGCR activities and plasma concentrations of MVA in ten patients (r = 0.83, P \< 0.01) ([@b83-aci-3-45]).

viii. The GC-EI-MS method did not require frequent cleaning. This indicated that the GC-EI-MS method was suitable for clinical applications, in which it is necessary to assay a large number of samples at once.

LC-MS and LC-MS/MS
------------------

Since the early 2000s, LC-MS or LC-MS/MS have been used more extensively than GC-MS to analyze relatively polar compounds, such as MVA or MVL, because LC-MS and LC-MS/MS do not generally require a derivatization step.

Park et al. ([@b55-aci-3-45]) and Ndong-Akoume et al. ([@b46-aci-3-45]) assessed HMGCR activity by measuring MVL with LC-MS and LC-MS/MS using the positive electrospray ionization (P-ESI) mode. Plasma and urinary MVA concentrations were quantified by LC-P-ESI-MS/MS after conversion into MVL ([@b1-aci-3-45]), as well as directly by LC-negative (N)-ESI-MS/MS without lactonization ([@b33-aci-3-45]; [@b62-aci-3-45]). The detection limit of MVL by the LC-MS method was 6.5 pg ([@b55-aci-3-45]), and the lower limit of quantification of plasma MVA by the LC-MS/MS methods were 200--500 pg/mL, which were similar to those obtained using GC-MS methods.

Recently, we developed a highly-sensitive method to assess HMGCR activity by LC-MS/MS ([@b29-aci-3-45]). In this method, MVA was extracted as MVL and its detection sensitivity was enhanced through derivatization ([Fig. 1](#f1-aci-3-45){ref-type="fig"}). The features of this method are described below.

i.  The P-ESI mode was selected to quantify MVA because the positive mode provides more abundant ions than the negative mode ([@b26-aci-3-45]).

ii. To select the most suitable derivative of MVA for P-ESI mode, the amidation reaction from MVA via MVL, a characteristic reaction for γ-hydroxy fatty acids such as MVA, was conducted using seven types of primary alkylamines with a tertiary amine moiety to promote protonation. Of these amide derivatives, mevaonyl-2-pyrrolidin-1-yl-ethyl)-amide (MV-PLEA) was the best derivative for the LC-P-ESI-MS/MS method.

iii. The detection limit of this MV-PLEA was about 30 fg (signal-to-noise ratio (S/N) = 3), indicating that this is the most sensitive method at present for the detection of MVL.

iv. \[^2^H~7~\]MVL was used as an internal standard. The recovery of spiked MVA was 94.6%, and the relative standard deviations between sample preparations and between measurements by this method were 3.2% and 1.8%, respectively.

v.  MV-PLEA was determined by selected reaction monitoring (SRM) using m/z 245 (M+H) as a precursor ion and m/z 227 (M+H--H~2~O) as a product ion, which almost completely eliminated the interfering peaks on the SRM chromatogram.

vi. Hepatic HMGCR activities in 11 normal rats were measured by both the RI and LC-P-ESI-MS/MS methods. The HMGCR activities obtained by the present method correlated well with those obtained by the conventional RI method (r = 0.93, P \< 0.0001). In the RI method, \[^14^C\]HMG-CoA is usually used as 30 dpm/pmol = 33.3 fmol/dpm. When the standard deviation of background noise is 2 dpm, the signal would be 6 dpm when the S/N = 3. Therefore, the detection limit of the conventional RI method is calculated to be 200 fmol (S/N = 3). In comparison, the detection limit of the LC-P-ESI-MS/MS method is 240 amol (S/N = 3), ∼800 times more sensitive than that of the conventional RI method.

HPLC
----

In 2005, Buffalini et al. reported a new method for the determination of HMGCR activity by HPLC ([@b9-aci-3-45]). In this method, MVL produced from unlabeled HMG-CoA was extracted and quantified by HPLC with a fixed ultraviolet (UV) detector (200 nm). This method does not require very expensive equipment, such as a mass spectrometer, but the detection limit of MVL is at least 100,000 times less than that by mass spectrometry.

The methods for the quantification of 7A
========================================

CYP7A1 activity has previously been assayed by measuring the radioactivity of 7A produced from exogenously added \[^14^C\]cholesterol by incubation with liver microsomes ([@b73-aci-3-45]). However, the extent of equilibration of exogenous labeled cholesterol with the endogenous cholesterol pool under different conditions still remains to be elucidated. To overcome this problem, several methods, i.e. a radioisotope derivative method, and GC-MS and HPLC methods, have been developed. These methods are able to measure the net amount of 7A produced from endogenous and exogenous cholesterol. [Table 2](#t2-aci-3-45){ref-type="table"} summarizes the previously reported methods for the direct determination of the mass of 7A in the liver (enzyme assay) or plasma.

Radioisotope derivative method
------------------------------

This technique can measure the net amount of 7A produced from exogenous \[^14^C\]cholesterol and endogenous unlabeled cholesterol ([@b39-aci-3-45]; [@b75-aci-3-45]). The resultant 7A was extracted, acetylated with \[^3^H\]acetic anhydride and purified by thin layer chromatography (TLC). The mass of 7A was calculated from the amount of radioactivity in the acetylated product based upon the specific radioactivity of the reagent.

GC-MS
-----

In 1974, Björkhem and Danielsson developed a method for the assay of hepatic CYP7A1 activity by GC-MS ([@b5-aci-3-45]). Their method was based on stable isotope dilution-mass spectrometry using \[^2^H~3~\]7A as an internal standard. In this method, 7A produced from endogenous microsomal cholesterol was extracted in organic solvent, purified by TLC, converted to the TMS ether derivative, and analyzed by GC-MS. In 1981, Sanghvi et al. reported an alternative method by GC-MS in which 7A produced from microsomal cholesterol was extracted with 5α-cholestane as an internal standard by organic solvent, converted to the TMS ether derivative, and quantified by SIM ([@b63-aci-3-45]). Meanwhile, Yamashita et al. measured hepatic CYP7A1 activity by GC-SIM using 5α-cholestane-3β,7β-diol as an internal standard ([@b82-aci-3-45]).

We also developed a new assay method for hepatic CYP7A1 activity by GC-HR-SIM ([@b27-aci-3-45]). As mentioned in the previous MVA section, this method made it possible to quantify simultaneously not only 7A but also MVA. \[^2^H~7~\]7A was used as an internal standard and 7A was converted into its DMES ether derivative before analysis by GC-HR-MS. This DMES ether derivative was not only more stable but also much advantageous compared with the TMS ether derivative for the separation of 7A from contaminated cholesterol on GC chromatograms.

The concentration of 7A in human serum was first quantified by Björkhem et al. using GC-SIM ([@b7-aci-3-45]). They also showed that serum free (unesterified) 7A reflected hepatic CYP7A1 activities in humans. In contrast, Oda et al. quantified human serum free and esterified 7A concentrations by GC-SIM and reported that the hepatic CYP7A1 activities correlated better with the serum esterified 7A than with the free 7A ([@b50-aci-3-45]).

In 1993, we applied our GC-HR-SIM method to the determination of human serum 7A concentrations and confirmed that there was a significant correlation (r = 0.76, p \< 0.05) between serum free 7A concentrations and hepatic CYP7A1 activities in humans ([@b83-aci-3-45]). However, neither the esterified 7A (r = 0.45, p \> 0.05) nor the total (free + esterified) 7A concentrations (r = 0.51, p \> 0.05) correlated significantly with CYP7A activities.

HPLC
----

The assay method for hepatic CYP7A1 activity by HPLC was first reported by Noshiro et al. ([@b48-aci-3-45]). The 7A produced from microsomal cholesterol was extracted and separated by normal phase HPLC. Although the absorption maximum of 7A was lower than 200 nm, they monitored 7A at 214 nm because there was an interference due to absorption of oxygen and/or solvent impurities at lower wavelengths.

In 1986, the same group improved the assay method by converting the produced 7A into C4 by incubating with cholesterol oxidase ([@b51-aci-3-45]). Because C4 exhibits an intense absorption at 240 nm and there are fewer interfering peaks at this wavelength than at 214 nm, this improved method exhibited a more than 10-fold increase in the sensitivity compared with the previous one ([@b48-aci-3-45]). In 1989, Hylemon et al. modified Ogishima's method by using reverse-phase HPLC and adding 7β-hydroxycholesterol as an internal standard ([@b31-aci-3-45]).

The Methods for the Quantification of C4
========================================

Another plasma or serum marker for the evaluation of hepatic CYP7A1 activities is C4, which is a product of the next oxidative enzymatic reaction after CYP7A1. In fact, CYP7A1 activities correlated better with serum C4 levels compared with those of 7A irrespective of the esterification ([@b84-aci-3-45]). [Table 3](#t3-aci-3-45){ref-type="table"} shows the previously described methods for the quantification of serum C4 concentrations by HPLC, GC-MS, and LC-MS/MS.

HPLC
----

In 1988, Axelson et al. ([@b3-aci-3-45]) reported a method for the quantification of plasma C4 using normal-phase HPLC with UV detection, and demonstrated that plasma C4 concentration reflected bile acid biosynthesis in humans. In addition, they reported that there was a strong positive correlation between the plasma levels of C4 and the activities of CYP7A1 in patients treated with cholestyramine, chenodeoxycholic acid, or ursodeoxycholic acid ([@b4-aci-3-45]). However, their method required the addition of ^3^H-labeled 25-hydroxyvitamin D~3~ as an internal standard. On the other hand, Pettersson et al. ([@b58-aci-3-45]) and Gälman et al. ([@b19-aci-3-45]) used unlabeled 7β-hydorxy-4-cholesten-3-one as an internal standard and analyzed C4 levels using HPLC with a reversed-phase column. The detection limits of C4 by these HPLC-UV methods were nearly 1 ng, so that at least 1 mL of plasma was required for each assay.

GC-MS
-----

In 1994, we developed a more sensitive method for the quantification of plasma C4 by GC-HR-MS using \[^2^H~7~\]C4 as an internal standard ([@b84-aci-3-45]). C4 was extracted from 200 μL of plasma by a salting-out extraction, and then purified by serial solid-phase extractions. The extract was treated with O-methylhydroxylamine hydrochloride and then dimethylethylsilylated. The resulting methyloxime-DMES ether derivative was quantified by GC-HR-SIM. This method was very sensitive as well as specific, and a lower limit of detection of 1 pg was achieved.

We compared the relationships between hepatic CYP7A1 activity and plasma concentrations of C4 and free 7A in humans using our GC-HR-SIM methods ([@b84-aci-3-45]). Both biomarkers correlated significantly with hepatic CYP7A1 activity (C4: r = 0.84, p \< 0.001; free 7A: r = 0.73, p \< 0.01), and C4 correlated better with CYP7A1 activity compared with free 7A. However, perhaps these plasma markers do not precisely reflect hepatic CYP7A1 activities in some patients with markedly changed concentrations of plasma lipoproteins. Because plasma oxysterols including C4 and 7A are transported in lipoproteins, the concentrations of oxysterols can be affected by the half-life of the lipoproteins. This hypothesis was supported by another study by ourselves ([@b28-aci-3-45]), in which plasma C4 concentrations and hepatic CYP7A1 activities were compared in New Zealand white rabbits that were fed a high cholesterol diet and/or a bile fistula was constructed. Feeding cholesterol markedly increased and bile drainage reduced plasma cholesterol concentrations. Initially, in these models there was no correlation between plasma C4 concentrations and hepatic CYP7A1 activities (r = −0.24, p \> 0.05). Cholesterol feeding was associated with downregulated CYP7A1 activities, while plasma C4 concentrations were elevated in the presence of increased plasma cholesterol levels. However, this discrepancy was overcome and a significant correlation was observed (r = 0.73, p \< 0.05) by expressing C4 levels relative to cholesterol. These results suggested that plasma C4 relative to cholesterol was a better marker for hepatic CYP7A1 activity than the absolute concentration when plasma cholesterol concentrations were changed markedly.

LC-MS/MS
--------

HPLC with UV detection is a more convenient method than GC-MS for the measurement of plasma C4 concentrations. However, the sensitivity is not sufficient to quantify C4 in limited amounts of human serum. Therefore, we recently developed a highly-sensitive new method by LC-MS/MS ([@b30-aci-3-45]). After the addition of \[^2^H~7~\]C4 as an internal standard, C4 was extracted from human serum (2--50 μL) by a salting-out procedure, derivatized into the picolinoyl ester (C4--7α-picolinate), and then purified using a disposable C~18~ cartridge. The resulting picolinoyl ester derivative of C4 was quantified by LC-P-ESI-MS/MS ([Fig. 2](#f2-aci-3-45){ref-type="fig"}). LC-MS/MS method do not always require a derivatization step. However, it is also true that the introduction of charged moieties enhances the ionization efficiency of neutral steroids in ESI and atmospheric pressure chemical ionization processes. In P-ESI mode, the picolinoyl ester of C4 exhibited an \[M+H\]^+^ ion at *m/z* 506 as the base peak. In the MS/MS spectrum, the \[M--C~6~H~5~O~2~N\]^+^ ion was observed at *m/z* 383 as the most prominent peak. The SRM was conducted using *m/z* 506 → *m/z* 383 for the C4--7α-picolinate and *m/z* 513 → *m/z* 390 for the \[^2^H~7~\] variant. The detection limit of the C4--7α-picolinate was 30 fg (S/N = 3), which was more than 1,000 times more sensitive than that of C4 with a conventional HPLC-UV method. The recovery of spiked C4 was 93.4%, and the relative standard deviations between sample preparations and between measurements by this method were 5.7% and 3.9%, respectively. Thus, this LC-MS/MS method is not only the most sensitive method at present for the detection of C4 but it is also highly reliable and reproducible.

Applications to Clinical Studies
================================

The quantification of MVA, 7A or C4 in human blood has made it possible to monitor *in vivo* cholesterol and bile acid synthesis without the need for an invasive liver biopsy. Therefore, these methods are very useful for basic or clinical time-course studies of cholesterol metabolism ([Table 4](#t4-aci-3-45){ref-type="table"}).

Diurnal cycle
-------------

In 1982, Parker et al. observed the diurnal cycle of the MVA concentrations in human plasma ([@b56-aci-3-45]). At the peak of the cycle (between midnight and 3 a.m.), the MVA concentrations were 3--5 times greater than those at the nadir (between 9 a.m. and noon). Pappu et al. also reported that the plasma concentrations of MVA exhibited a diurnal cycle in normal subjects and patients with abetalipoproteinemia, and the highest levels were observed between midnight and 4 a.m. ([@b53-aci-3-45]).

On the other hand, the diurnal cycle of bile acid biosynthesis in the human liver was reported (deletion) by Duane et al. ([@b13-aci-3-45]). They used a radioisotope technique and demonstrated for the first time that humans with an intact enterohepatic circulation exhibited a diurnal cycle of bile acid synthesis with an amplitude of ± 35%--55% around mean synthesis, and an acrophase at about 9 a.m. The same group also reported in 1988 that neither chenodeoxycholic acid nor ursodeoxycholic acid administration significantly altered the circadian rhythm of bile acid synthesis in humans ([@b60-aci-3-45]).

We investigated the diurnal cycle of bile acid biosynthesis by using plasma C4 and 7A concentrations ([@b84-aci-3-45]). Plasma was obtained every 2 hours from three normal volunteers and the C4 and 7A concentrations were determined using our GC-HR-MS method ([Fig. 3](#f3-aci-3-45){ref-type="fig"}). These levels were fitted to a cosine curve as reported in the previous studies using the isotope kinetic method ([@b13-aci-3-45]; [@b60-aci-3-45]). The amplitudes of C4 and free 7A averaged 45% and 32%, respectively, and the acrophases of C4 and free 7A averaged 5:35 a.m. and 5:39 a.m., respectively, which was compatible with the previous results obtained using the radioisotope technique ([Fig. 4](#f4-aci-3-45){ref-type="fig"}). In contrast, total 7A and esterified 7A did not exhibit any significant diurnal cycle.

In 2005, Gälman et al. also reported the diurnal cycle of C4 and lathosterol, another biomarker of cholesterol biosynthesis ([@b21-aci-3-45]). They concluded that bile acid synthesis in humans exhibits a diurnal cycle with 2 peaks during the daytime, which is opposite from the circadian rhythm of cholesterol biosynthesis. These results were different from previous studies. Further investigations will be required to elucidate the reason for the discrepancy.

HMGCR inhibitors
----------------

The measurement of plasma MVA concentration is very useful to evaluate the *in vivo* effects of HMGCR inhibitors. Pfohl et al. reported that the HMGCR inhibitor, simvastatin, rapidly down-regulated cholesterol biosynthesis, which was then up-regulated when the drug was withdrawn ([@b59-aci-3-45]). Nozaki et al. investigated the difference in the effect of another HMGCR inhibitor, pravastatin, on cholesterol biosynthesis between the morning and the evening. They administered pravastatin to the same patients in the morning or evening, and found that morning and evening administrations of pravastatin elicited equivalent reductions in the plasma and urinary MVA concentrations ([@b49-aci-3-45]). Pappu and Illingworth demonstrated that patients with familial hypercholesterolemia exhibited a diurnal pattern in plasma MVA levels similar to that reported previously in controls ([@b54-aci-3-45]). In addition, they reported that the administration of lovastatin in the evening reduced the nocturnal increases in MVA levels, and the administration of simvastatin completely abolished the nighttime rise. Naoumova et al. treated familial hypercholesterolemia patients with 3 different HMGCR inhibitors, pravastatin, simvastatin, and atorvastatin, and showed that the patients who responded well to statins exhibited higher basal plasma levels of MVA ([@b42-aci-3-45]).

We investigated the short-term effects of pravastatin on cholesterol and bile acid biosynthesis by measuring MVA and C4 as biomarkers ([@b85-aci-3-45]). Six male volunteers were administered 40 mg of pravastatin, and the plasma MVA and C4 levels were measured every 2 hours. The plasma MVA levels 2 hours after the administration of pravastatin were decreased compared with those in controls. While the decrease in MVA concentrations continued for 8 hours, the plasma C4 concentrations did not change during the initial 6 hours and then decreased 8 hours after the administration. Three-way analysis of this study indicated that the MVA level was influenced significantly by both pravastatin treatment and the time-course. In contrast, C4 level was affected significantly by both inter-individual differences and time-course, but not by pravastatin treatment. These results indicated that cholesterol biosynthesis was inhibited by pravastatin treatment, but bile acid biosynthesis was not influenced in normal subjects ([@b85-aci-3-45]). Naoumova et al. treated familial hypercholesterolemia patients with atorvastatin and partial ileal bypass ([@b45-aci-3-45]). Atorvastatin decreased the rate of bile acid synthesis only when bile acid synthesis was up-regulated by partial ileal bypass or bile acid sequestrants, presumably by limiting the supply of newly synthesized free cholesterol.

Hormones
--------

There are several reports that show the effects of hormones e.g. insulin, growth hormone and thyroid hormone, on *in vivo* cholesterol metabolism. Euglycemic hyperinsulinemia acutely decreased the circulating levels of MVA ([@b35-aci-3-45]), which indicated that insulin could decrease cholesterol biosynthesis. Naoumova et al. also investigated the effects of hyperinsulinemia on the plasma MVA concentrations and reported that acute hyperinsulinemia decreased cholesterol biosynthesis less in the subjects with non-insulin-dependent diabetes mellitus compared with non-diabetic subjects, which suggests that the patients with non-insulin-dependent diabetes mellitus exhibit insulin resistance ([@b42-aci-3-45]).

Because plasma growth hormone levels and cholesterol biosynthesis are both increased during sleep, Boyle et al. speculated that growth hormone might stimulate *de novo* cholesterol biosynthesis ([@b8-aci-3-45]). However, the peak nocturnal and fasting MVA concentrations did not correlate with the growth hormone levels, and they concluded that nocturnal growth hormone secretion was not related to the stimulation of cholesterol production during sleep.

Patients with hypothyroidism exhibit hypercholesterolemia, while those with hyperthyroidism exhibit hypocholesterolemia. Sauter et al. measured serum C4 concentrations before and after treatment for hypo- and hyperthyroidism and showed that in humans, thyroid hormones influenced the serum cholesterol concentrations by mechanisms other than through modification of the CYP7A1 activity ([@b66-aci-3-45]).

Bile acids
----------

Bile acids, particularly chenodeoxycholic acid (CDCA) and deoxycholic acid (DCA), are physiological ligands for the farnesoid X receptor (FXR, NR1H4). They inhibit bile acid biosynthesis through activation of this nuclear receptor. In fact, Einarsson et al. reported that the treatment of healthy subjects with CDCA or DCA reduced the serum concentrations of C4 ([@b15-aci-3-45]). They also found that CDCA reduced cholesterol biosynthesis while DCA did not when they evaluated *in vivo* cholesterol biosynthesis by measuring the serum 7-dehydrocholesterol concentrations. In contrast, UDCA treatment for 40 days did not affect cholesterol synthesis, as evaluated by urinary excretion of MVA, but the same treatment significantly increased bile acid biosynthesis determined by serum C4 concentrations ([@b68-aci-3-45]).

Hepatobiliary diseases
----------------------

Cholesterol gallstone disease is caused by abnormal cholesterol and bile acid metabolism. The formation of cholesterol supersaturated bile is one of the important factors in the pathogenesis of this disease. Shoda et al. proposed an estimated biliary cholesterol saturation index (CSI)~E~ = 1\[MVL\] + 0.7\[C4\] that was calculated by multivariate linear regression analysis using the plasma MVA and C4 concentrations of patients with hyperlipoproteinemia and demonstrated that this convenient calculation of (CSI)~E~ corresponded well to actual biliary CSI ([@b77-aci-3-45]). However, the hypersecretion of biliary cholesterol in patients with gallstones does not seem to be due to increased hepatic synthesis of cholesterol or decreased catabolism of cholesterol to bile acids. This could be because the plasma levels of lathosterol were not significantly different between gallstone subjects and controls and the C4 levels were about 40% higher in the gallstone subjects compared with the controls ([@b41-aci-3-45]). The increased bile acid biosynthesis determined by the plasma C4 levels, corrected for plasma cholesterol, was also reported in gallstone subjects and gallstone high-risk Mapuche Indians ([@b20-aci-3-45]).

Conversely, some hepatobiliary diseases affect cholesterol and bile acid metabolism. In patients with liver cirrhosis (LC), the blood cholesterol levels are relatively preserved, despite other markers, including the serum albumin levels, show liver dysfunction. We studied the association between hepatic cholesterogenesis and bile acid synthesis in hepatocellular impairment using the plasma levels of MVA and C4 ([@b86-aci-3-45]). There were no significant differences in the plasma MVA levels between chronic hepatitis (CH), LC and control groups. In contrast, plasma C4 levels were significantly lower in LC compared with the CH and control groups. Although the MVA levels did not correlate with the Child-Pugh's score, which reflects the severity of liver damage ([@b2-aci-3-45]), there was a significant correlation between the C4 level and Child-Pugh's score. In addition, plasma C4 levels in the control subjects correlated positively with the MVA levels, but there was no significant correlation between these biomarkers in CH and LC patients. Therefore, it was concluded that in the patients with chronic liver disease, there was a tendency for hepatic cholesterogenesis to be sustained in the face of hepatocellular dysfunction, while bile acid synthesis declined in parallel with the severity of impairment.

Perspectives
============

Biological specimens contain many types of organic acids and sterols. While fatty acids and cholesterol are relatively abundant compounds, MVA and oxysterols (7A and C4) are minor components. To quantify the concentrations of such minor components, stable isotope dilution mass spectrometry (GC-MS or LC-MS/MS) is an ideal method because of its high sensitivity, specificity and accuracy.

Recently, LC-MS/MS has come to be used more readily than GC-MS. Because MS/MS is more specific than MS, sample preparation process for the elimination of interfering materials can be simplified. In addition, LC-MS/MS does not require a derivatization step, which is also advantageous for high-throughput analyses. However, simple and rapid procedures do not always produce good results for the microanalysis of biological samples. A careful sample purification can increase the sensitivity of an analyte by reducing matrix effect ([@b33-aci-3-45]). Derivatization is useful not only to increase the sensitivity by enhancing the ionization efficiency but also to give a prominent ion in the high mass region, which makes it possible to avoid interfering peaks and to increase the specificity. A thorough chromatographic separation is also important to distinguish between similar biological compounds, e.g. hydroxycholesterols that have the same molecular weight and a virtually identical MS/MS spectrum. Thus, the importance of basic analytical techniques, i.e. sample purification, derivatization and chromatographic separation will not be denied even if the performance of mass spectrometer is improved further.

In conclusion, the methods for the quantification of key intermediates in cholesterol and bile acid biosynthetic pathways using stable isotope dilution mass spectrometry exhibit superior accuracy and sensitivity. By using this technique, the MVA and oxysterols in blood were established as biomarkers for cholesterol and bile acid biosynthesis. The use of these biomarkers has made it possible to monitor *in vivo* cholesterol and bile acid synthesis without the need for invasive liver biopsy, which is very useful for basic or clinical studies of cholesterol metabolism in humans.

![Representative chromatogram of mevalonyl-(2-pyrrolidin-1-yl-ethyl)-amide (MV-PLEA) by positive ESI-SRM at *m/z* 245 → *m/z* 227. Authentic standard of MV-PLEA (100 fg) was injected into the HPLC. LC-MS/MS conditions have been described previously ([@b29-aci-3-45]).](aci-3-45f1){#f1-aci-3-45}

![Representative chromatogram of C4-7α-picolinate by positive ESI-SRM at *m/z* 506 → *m/z* 383. Authentic standard of C4--7α-picolinate (100 fg) was injected into HPLC. LC-MS/MS conditions have been described previously ([@b30-aci-3-45]).](aci-3-45f2){#f2-aci-3-45}

![The circadian rhythm of the plasma levels of C4 and 7A in three normal volunteers. The volunteers consumed a normal hospital diet three times a day (shown by arrows), and slept from 21:00 on the first day to 6:00 on the second day (shown by the shaded box). The values are expressed as fractional variations around the mean levels (mean ± SD). Dashed lines represent the curves of best fit. (**A**) C4; (**B**) free 7A; (**C**) esterified 7A; (**D**) total 7A. Reprinted with minor modification from our previous paper ([@b84-aci-3-45]), Copyright (1994), with permission from Elsevier.](aci-3-45f3){#f3-aci-3-45}

![The curves of best fit for C4 and 7A. (**A**) C4, y = 0.46 cos ((2π/24)t − 1.46) (p \< 0.005); (**B**) Free 7A, y = 0.32 cos ((2π/24)t − 1.48) (p \< 0.005); (**C**) Esterified 7A, 0.12 cos ((2π/24)t + 0.97) (NS); (**D**) Total 7A, 0.07 cos ((2π/24)t − 0.65) (NS). Statistical significance was evaluated by a Zero-amplitude test by Nelson et al. ([@b47-aci-3-45]). Reprinted with minor modification from our previous paper ([@b84-aci-3-45]), Copyright (1994), with permission from Elsevier.](aci-3-45f4){#f4-aci-3-45}

###### 

Methods for quantification of MVA in biological samples.

  **Author**            **Year**          **Method (ionization mode)**   **Derivatization**       **Lower limit of detection**   **Intra-assay variation**   **Inter-assay variation**   **Recovery**   **Application**
  --------------------- ----------------- ------------------------------ ------------------------ ------------------------------ --------------------------- --------------------------- -------------- -----------------
  Hagenfeldt et al.     [@b23-aci-3-45]   GC-MS (P-EI)                   MVL                      NA                             NA                          6.2%                        87% ± 4%       blood
  Miyazaki et al.       [@b40-aci-3-45]   GC-MS (P-CI)                   MVL-PABB                 NA                             NA                          NA                          NA             liver
  Popjak et al.         [@b61-aci-3-45]   radioenzymatic assay           5-\[^32^P\]phospho-MVA   150--300 pg                    NA                          NA                          100%           plasma
  Cighetti et al.       [@b10-aci-3-45]   GC-MS (P-EI)                   MVL-TMS                  NA                             1.5%                        6.1%                        NA             liver
  Del Puppo et al.      [@b11-aci-3-45]   GC-HR-MS (P-EI)                MVL-TMS                  NA                             6.5%                        NA                          101% ± 4%      plasma urine
  Honda et al.          [@b27-aci-3-45]   GC-HR-MS (P-EI)                MVL-B-DMES               800 fg                         4.9%                        7.8%                        96%--100%      liver
  Scoppola et al.       [@b70-aci-3-45]   GC-MS (N-CI)                   MVA-TFB-TMS              10 pg                          5.1%                        7.7%                        NA             plasma
  Yoshida et al.        [@b83-aci-3-45]   GC-HR-MS (P-EI)                MVL-B-DMES               NA                             2.8%                        5.6%                        91%--96%       plasma
  Ishihama et al.       [@b32-aci-3-45]   GC-MS (P-CI)                   MVL                      NA                             2.2%                        4.5%                        101%--103%     plasma
  Siavoshian et al.     [@b78-aci-3-45]   GC-MS (P-CI)                   MVL-TMS                  NA                             4.0%                        8.0%                        70% ± 2%       urine
  Saisho et al.         [@b64-aci-3-45]   GC-MS (N-CI)                   MVA-PFB-CB               NA                             2.0%                        7.5%                        100%--107%     plasma
  Hiramatsu et al.      [@b25-aci-3-45]   enzyme immunoassay             MVA                      195 pg                         3.4%                        5.2%                        102% ± 7%      urine
  Woollen et al.        [@b81-aci-3-45]   GC-MS (P-EI)                   MVL                      NA                             \<13.7%                     \<9.8%                      82%--110%      urine
  Park et al.           [@b55-aci-3-45]   LC-MS (P-ESI)                  MVL                      6.5 pg                         4.1%                        9.4%                        95% ± 4%       liver
  Ndong-Akoume et al.   [@b46-aci-3-45]   LC-MS/MS (P-ESI)               MVL                      NA                             \<1.0%                      NA                          98%--99%       liver
  Abrar et al.          [@b1-aci-3-45]    LC-MS/MS (P-ESI)               MVL                      NA                             4.1%--15%                   13%--16%                    89%--114%      plasma
  Jemal et al.          [@b33-aci-3-45]   LC-MS/MS (N-ESI)               MVA                      NA                             \<4.5%                      \<3.3%                      98%--103%      plasma urine
  Buffalini et al.      [@b9-aci-3-45]    HPLC-UV                        MVL                      741 ng                         NA                          \<3.0%                      97%--103%      liver
  Saini et al.          [@b62-aci-3-45]   LC-MS/MS (N-ESI)               MVA                      NA                             1%--17%                     3%--12%                     99%--108%      plasma
  Honda et al.          [@b29-aci-3-45]   LC-MS/MS (P-ESI)               MV-PLEA                  31 fg                          1.8%                        3.2%                        93%--96%       liver

**Abbreviations:** P-EI: positive electron ionization; NA: not available; P-CI: positive chemical ionization; N-CI: negative chemical ionization; MVL-PABB: MVL n-propylamide-n-butylboronate; MVL-TMS: trimethylsilyl ether of MVL; GC-HR-MS: high-resolution GC-MS; MVL-B-DMES: dimethylethylsilyl ether of mevalonylbenzylamide; MVA-TFB-TMS: trimethylsilyl ether of bis(trifluoromethyl)benzyl ester of MVA; MVA-PFB-CB: cyclic boronate-pentafluorobenzyl ester of MVA; P-ESI: positive electrospray ionization; N-ESI: negative electrospray ionization; HPLC-UV: high-performance liquid chromatography equipped with an ultraviolet detector; MV-PLEA: MV-(2-pyrrolidin-1-yl-ethyl)-amide.

###### 

Methods for quantification of 7A in biological samples.

  **Author**           **Year**          **Method (ionization mode)**     **Derivatization**   **Lower limit of detection**   **Intra-assay variation**   **Inter-assay variation**   **Recovery**   **Application**
  -------------------- ----------------- -------------------------------- -------------------- ------------------------------ --------------------------- --------------------------- -------------- -----------------
  Mitropoulos et al.   [@b39-aci-3-45]   radioisotope derivative method   acetylated 7A        NA                             NA                          NA                          NA             liver
  Björkhem et al.      [@b5-aci-3-45]    GC-MS (P-EI)                     7A-TMS               NA                             NA                          2.2%                        95%            liver
  Sanghvi et al.       [@b63-aci-3-45]   GC-MS (P-EI)                     7A-TMS               50 pg                          3.5%                        2.3%--4.7%                  NA             liver
  Noshiro et al.       [@b48-aci-3-45]   NP-HPLC-UV                       7A                   NA                             NA                          NA                          385%           liver
  Ogishima et al.      [@b51-aci-3-45]   NP-HPLC-UV                       C4                   NA                             NA                          NA                          NA             liver
  Björkhem et al.      [@b6-aci-3-45]    GC-MS (P-EI)                     7A-TMS               1--2 ng/mL                     NA                          4%--8%                      105%           serum
  Hylemon et al.       [@b31-aci-3-45]   RP-HPLC-UV                       C4                   8 ng                           NA                          NA                          NA             liver
  Yamashita et al.     [@b82-aci-3-45]   GC-MS (P-EI)                     7A-TMS               NA                             3.8%                        4.6%                        92%--99%       liver
  Oda et al.           [@b50-aci-3-45]   GC-MS (P-EI)                     7A-TMS               NA                             NA                          3%                          97%--109%      serum
  Honda et al.         [@b27-aci-3-45]   GC-HR-MS (P-EI)                  7A-DMES              1.6 pg                         7.9%                        7.0%                        94%--102%      liver
  Yoshida et al.       [@b83-aci-3-45]   GC-HR-MS (P-EI)                  7A-DMES              NA                             4.2%                        2.6%                        93%--95%       serum

**Abbreviations:** NA: not available; P-EI: positive electron ionization; 7A-TMS: trimethylsilyl ether of 7α-hydroxycholesterol; HPLC-UV: high-performance liquid chromatography equipped with an ultraviolet detector; NP: normal-phase; C4: 7α-hydroxy-4-cholesten-3-one; RP: reversed-phase; GC-HR-MS: high-resolution GC-MS; 7A-DMES: dimethylethylsilyl ether of 7α-hydroxycholesterol

###### 

Methods for quantification of serum C4 concentration.

  **Author**          **Year**          **Method (ionization mode)**   **Derivatization**   **Lower limit of detection**   **Intra-assay variation**   **Inter-assay variation**   **Recovery**   **Application**
  ------------------- ----------------- ------------------------------ -------------------- ------------------------------ --------------------------- --------------------------- -------------- -----------------
  Axelson et al.      [@b3-aci-3-45]    NP-HPLC-UV                     C4                   0.5--1.5 ng/mL                 NA                          5%                          82%--106%      plasma
  Pettersson et al.   [@b58-aci-3-45]   RP-HPLC-UV                     C4                   3 ng                           3.2%                        3.8%                        96%--105%      serum
  Yoshida et al.      [@b84-aci-3-45]   GC-HR-MS (P-EI)                C4-MO-DMES           1 pg                           2.54%                       5.16%                       94%--100%      plasma
  Gälman et al.       [@b19-aci-3-45]   RP-HPLC-UV                     C4                   500 pg                         4.4%                        5.6%                        NA             blood
  Honda et al.        [@b29-aci-3-45]   LC-MS/MS (P-ESI)               C4-picolinate        30 fg                          3.9%                        5.7%                        92%--94%       serum

**Abbreviations:** HPLC-UV: high-performance liquid chromatography equipped with an ultraviolet detector; NA: not available; NP: normal-phase; RP: reversed-phase; GC-HR-MS: high-resolution GC-MS; P-EI: positive electron ionization; C4-MO-DMES: methyloxime dimethylethylsilyl ether of C4; P-ESI: positive electrospray ionization.

###### 

Applications of MVA and C4 as biomarkers for cholesterol and bile acid biosynthesis.

                                                  **MVA**     **C4**                                                **References**
  ----------------------------------------------- ----------- ----------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------
  HMGCR inhibitors                                decrease    --                                                    ([@b49-aci-3-45]; [@b42-aci-3-45]; [@b85-aci-3-45]; [@b44-aci-3-45]; [@b59-aci-3-45]; [@b52-aci-3-45]; [@b54-aci-3-45])
  --                                              no effect   ([@b85-aci-3-45]; [@b45-aci-3-45]; [@b52-aci-3-45])   
  HMGCR inhibitors with partial ileal resection   decrease    decrease                                              ([@b45-aci-3-45])
  Insulin                                         decrease    --                                                    ([@b35-aci-3-45]; [@b71-aci-3-45]; [@b42-aci-3-45])
  Growth hormone                                  no effect   --                                                    ([@b8-aci-3-45])
  --                                              no effect   ([@b36-aci-3-45]; [@b37-aci-3-45])                    
  Thyroid hormone                                 --          no effect                                             ([@b66-aci-3-45])
  CDCA                                            --          decrease                                              ([@b15-aci-3-45])
  DCA                                             --          decrease                                              ([@b15-aci-3-45])
  UDCA                                            --          increase                                              ([@b68-aci-3-45])
  Rifampin                                        --          increase                                              ([@b38-aci-3-45])
  Gallstone                                       --          increase                                              ([@b41-aci-3-45]; [@b20-aci-3-45])
  Liver cirrhosis                                 no change   decrease                                              ([@b86-aci-3-45])
  Diarrhea                                        --          increase                                              ([@b16-aci-3-45]; [@b67-aci-3-45])
